Finalist
HER2Know.com: Medical Education to Support HER2 Evolution in Breast Cancer
Summary of work
HER2Know is a unique educational initiative developed in consultation with a faculty of pathologists from across the United States, selected for their expertise in breast cancer. It encompasses a website and educational materials that provide information and education on the evolution of the clinical significance of HER2, helping to educate the pathology community.
Historically, the binary classification of HER2 (positive or negative) in breast cancer has meant that only 15% of patients with metastatic breast cancer can receive HER2-targeted treatment. However, up to 60% of patients with HER2-negative metastatic breast cancer have low levels of HER2 expression. We had to shift the mindset of pathologists to look beyond the binary ‘positive’ and ‘negative’ towards a spectrum of expression.
Judges’ comments
The judges liked the HER2Know.com’s engaging documentary and full suite of materials. It had a consistent approach, with a strong delivery. It was clear it made a difference and was a solid professional education programme.
